Analyst Price Targets — OCUL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 1:55 pm | Lisa Walter | RBC Capital | $30.00 | $9.30 | StreetInsider | RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity |
| December 8, 2025 11:14 am | — | H.C. Wainwright | $21.00 | $12.58 | TheFly | Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright |
| October 8, 2025 10:07 am | — | H.C. Wainwright | $19.00 | $11.52 | TheFly | Ocular Therapeutix price target raised to $19 from $15 at H.C. Wainwright |
| October 3, 2025 11:51 am | — | Piper Sandler | $31.00 | $11.06 | TheFly | Ocular Therapeutix price target raised to $31 from $21 at Piper Sandler |
| October 3, 2025 11:10 am | Colleen Kusy | Robert W. Baird | $24.00 | $11.06 | TheFly | Ocular Therapeutix price target raised to $24 from $17 at Baird |
| October 1, 2025 9:57 am | Jonathan Wolleben | JMP Securities | $29.00 | $11.69 | TheFly | Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP |
| March 4, 2025 10:42 am | — | JMP Securities | $19.00 | $6.50 | TheFly | Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness |
| August 8, 2024 7:46 am | Colleen Kusy | Robert W. Baird | $17.00 | $8.37 | TheFly | Ocular Therapeutix price target lowered to $17 from $18 at Baird |
| June 27, 2024 9:31 am | Biren Amin | Piper Sandler | $15.00 | $6.71 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL) |
| June 14, 2024 7:57 am | Yi Chen | H.C. Wainwright | $14.00 | $5.89 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL) |
Latest News for OCUL
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI),…
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have issued a buy recommendation on
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price. The quarter-end value of position dropped by $65.05 million, reflecting both trading and Ocular Therapeutix share price changes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OCUL.
U.S. House Trading
No House trades found for OCUL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.